Johnson & Johnson AGM: CEO Duato touts “catalyst year,” 5.3% sales growth and $32B investment push

2 hours ago 1

MarketBeat

Sun, April 26, 2026 astatine 2:02 PM CDT 7 min read

Johnson & Johnson logo

CEO Joaquin Duato called 2025 a "catalyst year," reporting operational income up 5.3% (11.5% ex‑Stelara), adjusted nett net of $26.2 billion, astir $20 cardinal successful escaped currency flow, a 64th consecutive dividend increase, and much than $32 billion invested successful R&D and acquisitions with a program to put $55 billion successful the U.S. by aboriginal 2029.
Management highlighted beardown commercialized and pipeline momentum — including 51 approvals, 32 regulatory submissions, 28 platforms generating implicit $1 cardinal each (Darzalex >$14B; Carvykti has treated >10,000 patients) — alongside MedTech maturation and aggregate large merchandise launches.
Governance items passed: each 12 manager nominees were re‑elected and advisory wage and auditor ratification were approved portion a shareholder connection failed; the institution reiterated its unchanged presumption connected talc litigation aft returning to the tort strategy pursuing dismissal of its bankruptcy proceeding.
Interested successful Johnson & Johnson? Here are 5 stocks we similar better.

Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results

Johnson & Johnson (NYSE:JNJ) utilized its 2026 yearly gathering of shareholders to item what absorption described arsenic a “catalyst year” successful 2025, pointing to broad-based operational income growth, large merchandise launches and pipeline progress, and important superior deployment crossed research, acquisitions, and manufacturing.

Marc Larkins, worldwide vice president of firm governance and firm secretary, opened the gathering and noted shareholders could entree the agenda, rules of order, proxy statement, and yearly study done the gathering website. Larkins said the institution was joined by its enforcement committee, its committee of directors, and Jonathan Hirschfeld representing PricewaterhouseCoopers, the company’s autarkic auditor.

→ STMicronelectronics Sends Industrial Chips Into Overdrive

A Q2 2026 Playbook for Navigating Market Uncertainty

In prepared remarks, Chairman and CEO Joaquin Duato said 2025 sharpened the company’s absorption connected “six areas of precocious maturation and precocious unmet aesculapian need: oncology, immunology, neuroscience, cardiovascular, surgery, and vision.” Duato besides welcomed 2 caller committee members, John Morikis and Daniel Pinto.

Duato reported operational income grew 5.3% successful 2025, and “excluding Stelara, the institution grew 11.5%.” He said adjusted nett net were $26.2 cardinal and adjusted net per stock were $10.79. Duato besides cited astir $20 cardinal successful escaped currency travel and said the institution raised its dividend for the 64th consecutive year. He added that successful 2025 the stock terms roseate 43%, producing a full shareholder instrumentality of 47.5%, which helium described arsenic “one of the champion yearly returns successful our 82-year history” arsenic a publically traded company.

Read Entire Article